Enrolling by invitationPhase 2NCT07573631
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy
Studying Duchenne and Becker muscular dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BioMarin Pharmaceutical
- Intervention
- BMN 351(drug)
- Enrollment
- 18 enrolled
- Eligibility
- 4 years · MALE
- Timeline
- 2026 – 2031
Study locations (7)
- Fondazione Serena ETS - Centro Clinico NeMO Milano, Milan, Italy
- UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Rome, Italy
- Leids Universitair Medisch Centrum, Leiden, Netherlands
- Hospital Sant Joan de Deu, Barcelona, Spain
- Hospital Viamed Santa Angela De la Cruz, Seville, Spain
- Yeditepe University Kosuyolu Hospital, Istanbul, Turkey, Turkey (Türkiye)
- Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07573631 on ClinicalTrials.gov